NEW YORK, April 17, 2017 /PRNewswire/ --
Stock-Callers.com today presents the following Medical Laboratories and Research equities for review: Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO), Quintiles IMS Holdings Inc. (NYSE: Q), and PAREXEL International Corp. (NASDAQ: PRXL). These stocks are part of the Healthcare sector, which has received an "Outperform" rating from Charles Schwab on April 13th, 2017. As per the research firm, health care companies' balance sheets are solid, their stocks have offered attractive dividend yields, the sector's overall cost structure appears to have improved, and demand for health care products and services appears to be on the rise. Learn more about these stocks by downloading their free report at:
Santa Clara, California headquartered Agilent Technologies Inc.'s stock finished last Thursday's session 0.42% lower at $52.33. A total volume of 863,880 shares was traded. The Company's shares have advanced 8.12% over the previous three months and 15.14% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.12% and 10.38%, respectively. Additionally, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have a Relative Strength Index (RSI) of 48.45.
On March 20th, 2017, Agilent Technologies announced that Samraat "Sam" Raha has been named Senior Vice President of strategy and corporate development, reporting to Agilent President and CEO Mike McMullen. Raha will serve as strategic lead and advisor to the CEO and executive team in developing the Company's overall growth strategy, including leading its mergers and acquisitions plans globally. The free research report on A is available at:
On Thursday, shares in Waltham, Massachusetts headquartered Thermo Fisher Scientific Inc. ended the session 0.18% lower at $152.18. The stock recorded a trading volume of 934,603 shares. The Company's shares have gained 4.35% in the previous three months and 7.95% on an YTD basis. The stock is trading 0.66% above its 200-day moving average. Moreover, shares of Thermo Fisher Scientific, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide, have an RSI of 35.21.
On March 31st, 2017, Thermo Fisher Scientific announced that it will release its financial results for Q1 before the market opens on Wednesday, April 26th, 2017, and will hold a conference call on the same day at 8:30 a.m. ET. The call can be accessed live under the "Investors" section of the Company's website. The complimentary report on TMO can be downloaded at:
Durham, North Carolina headquartered Quintiles IMS Holdings Inc.'s shares gained 0.36%, closing the session at $78.95, with a total trading volume of 748,509 shares. The stock has gained 2.28% over the previous three months and 3.81% on an YTD basis. The Company's shares are trading 0.26% and 2.94% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Quintiles IMS Holdings, which provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and Asia/Pacific, have an RSI of 46.42.
On March 31st, 2017, research firm Credit Suisse initiated an 'Outperform' rating on the Company's stock, with a target price of $89 per share. Visit us today and download our complete research report on Q for free at:
Last Thursday at the close, shares in Waltham, Massachusetts headquartered PAREXEL International Corp. recorded a trading volume of 620,643 shares, and ended the session 1.18% lower at $61.10. The stock is trading below its 50-day moving average by 4.50%. Shares of the Company, which provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide, have an RSI of 34.18.
On March 23rd, 2017, research firm Mizuho initiated a 'Neutral' rating on the Company's stock, with a target price of $86 per share.
On April 03rd, 2017, PAREXEL International announced that it was named a top contract research organization (CRO) in the CenterWatch 2017 Global Investigative Site Relationship Survey. The Company ranked among the top five highest-rated CROs for the overall quality of its direct working relationships with investigative sites. Get free access to your technical report on PRXL at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA